Tang Capital Management’s LENZ Therapeutics LENZ Stock Holding History

Tang Capital Management’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.56M	Hold	451,114	–	–	0.12%	39
2026 Q1	$4.13M	Sell	451,114 -414,055	-48%	-$5.82M	0.21%	40
2025 Q4	$13.8M	Sell	865,169 -32,447	-4%	-$946K	0.68%	33
2025 Q3	$41.8M	Hold	897,616	–	–	1.61%	15
2025 Q2	$26.3M	Buy	897,616 +130,676	+17%	+$3.55M	1.33%	22
2025 Q1	$19.7M	Hold	766,940	–	–	1.09%	25
2024 Q4	$22.1M	Hold	766,940	–	–	1.47%	17
2024 Q3	$18.2M	Buy	766,940 +19,324	+3%	+$429K	1.3%	21
2024 Q2	$12.9M	Buy	747,616 +200,000	+37%	+$3.49M	1.32%	25
2024 Q1	$12.2M	Buy	547,616 +191,647	+54%	+$3.98M	1.27%	25
2023 Q4	$6.53M	Buy	355,969 +67,880	+24%	+$1.12M	0.6%	40
2023 Q3	$5M	Sell	288,089 -9,857	-3%	-$171K	0.71%	43
2023 Q2	$5.42M	Buy	297,946 +8,165	+3%	+$163K	0.8%	36
2023 Q1	$4.97M	Buy	289,781 +132,638	+84%	+$2.15M	0.74%	42
2022 Q4	$3.65M	Hold	157,143	–	–	0.53%	46
2022 Q3	$3.49M	Hold	157,143	–	–	0.43%	51
2022 Q2	$3.02M	Buy	+157,143	New	+$3.5M	0.46%	42

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

7IH

72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Tang Capital Management's LENZ Position: Q2 2026 in Review

Tang Capital Management held its LENZ Therapeutics (LENZ) position steady in Q2 2026 at 451,114 shares worth $2.56M. The position accounts for 0.12% of the portfolio, ranked #39.

Tang Capital Management first reported a position in LENZ in Q2 2022 and has held it in 17 quarters since. The position peaked at $41.8M in Q3 2025. 144 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

Tang Capital Management held 451,114 shares of LENZ Therapeutics worth $2.56M as of Q2 2026.
Tang Capital Management left its LENZ Therapeutics share count unchanged in Q2 2026.
LENZ Therapeutics made up 0.12% of Tang Capital Management's portfolio in Q2 2026, its #39 holding.
Tang Capital Management first reported a position in LENZ Therapeutics in Q2 2022 and has held it in 17 quarters since.
Tang Capital Management's LENZ Therapeutics position peaked at $41.8M in Q3 2025.
144 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Tang Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.